CA2484217A1 - Muscarinic antagonists - Google Patents

Muscarinic antagonists Download PDF

Info

Publication number
CA2484217A1
CA2484217A1 CA002484217A CA2484217A CA2484217A1 CA 2484217 A1 CA2484217 A1 CA 2484217A1 CA 002484217 A CA002484217 A CA 002484217A CA 2484217 A CA2484217 A CA 2484217A CA 2484217 A1 CA2484217 A1 CA 2484217A1
Authority
CA
Canada
Prior art keywords
alkyl
group
compound
compound according
cognitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002484217A
Other languages
English (en)
French (fr)
Inventor
Craig D. Boyle
William J. Greenlee
Samuel Chackalamannil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2484217A1 publication Critical patent/CA2484217A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CA002484217A 2002-04-26 2003-04-24 Muscarinic antagonists Abandoned CA2484217A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37609302P 2002-04-26 2002-04-26
US60/376,093 2002-04-26
PCT/US2003/012694 WO2003091220A1 (en) 2002-04-26 2003-04-24 Muscarinic antagonists

Publications (1)

Publication Number Publication Date
CA2484217A1 true CA2484217A1 (en) 2003-11-06

Family

ID=29270760

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002484217A Abandoned CA2484217A1 (en) 2002-04-26 2003-04-24 Muscarinic antagonists

Country Status (11)

Country Link
US (1) US6890936B2 (OSRAM)
EP (1) EP1499596B1 (OSRAM)
JP (2) JP4527408B2 (OSRAM)
CN (1) CN1649845A (OSRAM)
AT (1) ATE413388T1 (OSRAM)
AU (1) AU2003228674A1 (OSRAM)
CA (1) CA2484217A1 (OSRAM)
DE (1) DE60324544D1 (OSRAM)
ES (1) ES2315494T3 (OSRAM)
MX (1) MXPA04010552A (OSRAM)
WO (1) WO2003091220A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200701782A3 (ru) 2003-04-24 2008-04-28 Инсайт Корпорейшн Производные азаспироалканов в качестве ингибиторов металлопротеаз
AU2005287037A1 (en) * 2004-09-20 2006-03-30 Targacept, Inc. Azaspiroalkene and azaspiroalkane compounds with nicotinic cholinergic receptor activity
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20080103105A1 (en) * 2006-09-22 2008-05-01 Braincells, Inc. HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS
US20080108574A1 (en) * 2006-09-27 2008-05-08 Braincells, Inc. Melanocortin receptor mediated modulation of neurogenesis
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
TW200902007A (en) * 2007-05-25 2009-01-16 Astrazeneca Ab Spirocyclopropyl piperidine derivatives
US20100130477A1 (en) * 2008-11-25 2010-05-27 Astrazeneca Ab Spirocyclobutyl Piperidine Derivatives
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
CN102905532A (zh) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US20110281853A1 (en) 2010-05-12 2011-11-17 Rishi Arora Compositions and methods for treating or preventing atrial fibrillation
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
US10000477B2 (en) 2014-10-31 2018-06-19 Indivior Uk Limited Dopamine D3 receptor antagonist compounds
US10159648B2 (en) 2015-05-22 2018-12-25 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
WO2019014427A1 (en) * 2017-07-12 2019-01-17 Vanderbilt University ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
US11325896B2 (en) 2017-12-20 2022-05-10 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04225953A (ja) * 1990-05-07 1992-08-14 Shionogi & Co Ltd スピロ　ジベンゾスベラン誘導体
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
AU2206699A (en) * 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
US7164024B2 (en) * 2001-04-20 2007-01-16 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives

Also Published As

Publication number Publication date
JP4527408B2 (ja) 2010-08-18
JP2006507220A (ja) 2006-03-02
ES2315494T3 (es) 2009-04-01
DE60324544D1 (de) 2008-12-18
ATE413388T1 (de) 2008-11-15
MXPA04010552A (es) 2005-01-25
CN1649845A (zh) 2005-08-03
US20040067972A1 (en) 2004-04-08
JP2010059213A (ja) 2010-03-18
US6890936B2 (en) 2005-05-10
WO2003091220A1 (en) 2003-11-06
HK1068136A1 (en) 2005-04-22
EP1499596B1 (en) 2008-11-05
AU2003228674A1 (en) 2003-11-10
EP1499596A1 (en) 2005-01-26

Similar Documents

Publication Publication Date Title
EP1499596B1 (en) Muscarinic antagonists
EP1370528B1 (en) Mch antagonists and their use in the treatment of obesity
US6472394B1 (en) MCH antagonists and their use in the treatment of obesity
AU2002350269B2 (en) Piperidine -based MCH antagonists for treatment of obesity and CNS disorders
NZ530429A (en) Substituted urea neuropeptide Y Y5 receptor antagonists
EP1434766B1 (en) Piperidine compounds as muscarinic antagonists
EP3526203B1 (en) N-aryl and n-heteroaryl piperidine derivatives as liver x receptor beta agonists, compositions, and their use
NZ552059A (en) Piperidine derivatives as NK1 antagonists
AU2002348269A1 (en) N-aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity
CA2490470A1 (en) Pyrazole urea neuropeptide y y5 receptor antagonists
EP1532147A1 (en) Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
CA2517088A1 (en) Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders
US7345042B2 (en) MCH antagonists for the treatment of obesity
EP1902044A1 (en) 5-htx modulators
HK1068136B (en) Muscarinic antagonists
WO2006035280A1 (en) 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
AU2002244308A1 (en) MCH antagonists and their use in the treatment of obesity
HK1056877B (en) Mch antagonists and their use in the treatment of obesity
HK1071567B (en) Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued